Effects of green tea extract on insulin resistance and glucagon-like peptide 1 in patients with type 2 diabetes and lipid abnormalities: A randomized, double-blinded, and placebo-controlled trial

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Liu, Chia Yu ^a,b   Huang, Chien Jung ^b   Huang, Lin Huang ^a   Chen, I Ju ^a,b   Chiu, Jung Peng ^a,b   Hsu, Chung Hua ^a,b  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TAIPEI CITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ALANINE AMINOTRANSFERASE; ALPHA GLUCOSIDASE INHIBITOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; APOLIPOPROTEIN A1; APOLIPOPROTEIN B100; BIGUANIDE; CALCIUM CHANNEL BLOCKING AGENT; CELLULOSE; CHOLESTEROL; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV; FIBRIC ACID DERIVATIVE; GHRELIN; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; GREEN TEA EXTRACT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LEPTIN; MEGLITINIDE; ORAL ANTIDIABETIC AGENT; SULFONYLUREA; TRIACYLGLYCEROL; LIPID; PLACEBO; PLANT EXTRACT;

ABDOMINAL DISCOMFORT; ADULT; ANTHROPOMETRY; ARTICLE; BODY MASS; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; COMPARATIVE EFFECTIVENESS; CONSTIPATION; CONTROLLED STUDY; DISORDERS OF LIPID AND LIPOPROTEIN METABOLISM; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG MECHANISM; DRUG RESEARCH; EPIGASTRIC DISCOMFORT; FEMALE; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; GROWTH HORMONE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; DEMOGRAPHY; DIABETES MELLITUS, TYPE 2; METABOLISM; MIDDLE AGED;

DEMOGRAPHY; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INSULIN RESISTANCE; LIPIDS; MALE; MIDDLE AGED; PLACEBOS; PLANT EXTRACTS;

EID: 84897521018     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0091163     Document Type: Article

References (41)

1. Badulescu O, Badescu C, Ciocoiu M, Badescu M (2013) Interleukin-1-Beta and dyslipidemic syndrome as major risk factors for thrombotic complications in type 2 diabetes mellitus. Mediators Inflamm 2013: 169420.
2. Kreisberg RA (1998) Diabetic dyslipidemia. Am J Cardiol 82: 67U-73U; discussion 85U-86U.
3. Davidson M (2008) A review of the current status of the management of mixed dyslipidemia associated with diabetes mellitus and metabolic syndrome. Am J Cardiol 102: 19L-27L.
4. Khan N, Mukhtar H (2007) Tea polyphenols for health promotion. Life Sci 81: 519-533. (Pubitemid 47212236)
5. Jing Y, Han G, Hu Y, Bi Y, Li L, et al. (2009) Tea consumption and risk of type 2 diabetes: a meta-analysis of cohort studies. J Gen Intern Med 24: 557-562.
6. Ortsater H, Grankvist N, Wolfram S, Kuehn N, Sjoholm A (2012) Diet supplementation with green tea extract epigallocatechin gallate prevents progression to glucose intolerance in db/db mice. Nutr Metab (Lond) 9: 11.
7. Hursel R, Viechtbauer W, Dulloo AG, Tremblay A, Tappy L, et al. (2011) The effects of catechin rich teas and caffeine on energy expenditure and fat oxidation: a meta-analysis. Obes Rev 12: e573-581.
8. Hsu CH, Liao YL, Lin SC, Tsai TH, Huang CJ, et al. (2011) Does supplementation with green tea extract improve insulin resistance in obese type 2 diabetics? A randomized, double-blind, and placebo-controlled clinical trial. Altern Med Rev 16: 157-163.
9. Agin A, Jeandidier N, Gasser F, Grucker D, Sapin R (2006) Use of insulin immunoassays in clinical studies involving rapid-acting insulin analogues: Biinsulin IRMA preliminary assessment. Clin Chem Lab Med 44: 1379-1382. (Pubitemid 44706721)
10. Starr JI, Mako ME, Juhn D, Rubenstein AH (1978) Measurement of serum proinsulin-like material: cross-reactivity of porcine and human proinsulin in the insulin radioimmunoassay. J Lab Clin Med 91: 683-692.
11. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, et al. (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412-419. (Pubitemid 15018832)
12. Heijboer AC, Frans A, Lomecky M, Blankenstein MA (2011) Analysis of glucagon-like peptide 1; what to measure? Clin Chim Acta 412: 1191-1194.
13. Deacon CF, Holst JJ (2009) Immunoassays for the incretin hormones GIP and GLP-1. Best Pract Res Clin Endocrinol Metab 23: 425-432.
14. Yao G, Chung CW, Yu CF, Wang JD (2002) Development and verification of validity and reliability of the WHOQOL-BREF Taiwan version. J Formos Med Assoc 101: 342-351. (Pubitemid 34704858)
15. Pan HJ, Cole BM, Geliebter A (2011) The benefits of body weight loss on health-related quality of life. J Chin Med Assoc 74: 169-175.
16. Hsu CH, Tsai TH, Kao YH, Hwang KC, Tseng TY, et al. (2008) Effect of green tea extract on obese women: a randomized, double-blind, placebo-controlled clinical trial. Clin Nutr 27: 363-370.
17. Polonsky KS (2012) The past 200 years in diabetes. N Engl J Med 367: 1332-1340.
18. Consortium TI (2012) Tea consumption and incidence of type 2 diabetes in Europe: the EPIC-InterAct case-cohort study. PLoS One 7: e36910.
19. Phung OJ, Baker WL, Matthews LJ, Lanosa M, Thorne A, et al. (2010) Effect of green tea catechins with or without caffeine on anthropometric measures: a systematic review and meta-analysis. Am J Clin Nutr 91: 73-81.
20. Hursel R, Viechtbauer W, Westerterp-Plantenga MS (2009) The effects of green tea on weight loss and weight maintenance: a meta-analysis. International Journal of Obesity 33: 956-961.
21. Hsu CH, Liao YL, Lin SC, Tsai TH, Huang CJ, et al. (2011) Does supplementation with green tea extract improve insulin resistance in obese type 2 diabetics? A randomized, double-blind, and placebo-controlled clinical trial. Alternative Medicine Review 16: 157-163.
22. Ikeda I, Hamamoto R, Uzu K, Imaizumi K, Nagao K, et al. (2005) Dietary gallate esters of tea catechins reduce deposition of visceral fat, hepatic triacylglycerol, and activities of hepatic enzymes related to fatty acid synthesis in rats. Biosci Biotechnol Biochem 69: 1049-1053. (Pubitemid 41006986)
23. Yamaoka-Tojo M, Tojo T, Takahira N, Matsunaga A, Aoyama N, et al. (2010) Elevated circulating levels of an incretin hormone, glucagon-like peptide-1, are associated with metabolic components in high-risk patients with cardiovascular disease. Cardiovasc Diabetol 9: 17.
24. Baggio LL, Drucker DJ (2007) Biology of incretins: GLP-1 and GIP. Gastroenterology 132: 2131-2157. (Pubitemid 46711096)
25. Drucker DJ, Nauck MA (2006) The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368: 1696-1705. (Pubitemid 46048557)
26. Cernea S (2011) The role of incretin therapy at different stages of diabetes. Rev Diabet Stud 8: 323-338.
27. Kishimoto M, Noda M (2011) A pilot study of the efficacy of miglitol and sitagliptin for type 2 diabetes with a continuous glucose monitoring system and incretin-related markers. Cardiovasc Diabetol 10: 115.
28. Vilsboll T, Krarup T, Deacon CF, Madsbad S, Holst JJ (2001) Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 50: 609-613. (Pubitemid 32195226)
29. Rask E, Olsson T, Soderberg S, Johnson O, Seckl J, et al. (2001) Impaired incretin response after a mixed meal is associated with insulin resistance in nondiabetic men. Diabetes Care 24: 1640-1645. (Pubitemid 33716463)
30. Thondam SK, Cross A, Cuthbertson DJ, Wilding JP, Daousi C (2012) Effects of chronic treatment with metformin on dipeptidyl peptidase-4 activity, glucagonlike peptide 1 and ghrelin in obese patients with Type 2 diabetes mellitus. Diabet Med 29: e205-210.
31. Kappe C, Patrone C, Holst JJ, Zhang Q, Sjoholm A (2012) Metformin protects against lipoapoptosis and enhances GLP-1 secretion from GLP-1-producing cells. J Gastroenterol.
32. Brown AS (2005) Lipid management in patients with diabetes mellitus. Am J Cardiol 96: 26E-32E.
33. Imatoh T, Tanihara S, Miyazaki M, Momose Y, Uryu Y, et al. (2011) Coffee consumption but not green tea consumption is associated with adiponectin levels in Japanese males. Eur J Nutr 50: 279-284.
34. Sone T, Kuriyama S, Nakaya N, Hozawa A, Shimazu T, et al. (2011) Randomized controlled trial for an effect of catechin-enriched green tea consumption on adiponectin and cardiovascular disease risk factors. Food Nutr Res 55.
35. Wu AH, Spicer D, Stanczyk FZ, Tseng CC, Yang CS, et al. (2012) Effect of 2-month controlled green tea intervention on lipoprotein cholesterol, glucose, and hormone levels in healthy postmenopausal women. Cancer Prev Res (Phila) 5: 393-402.
36. Wu AH, Yu MC, Stanczyk FZ, Tseng CC, Pike MC (2011) Anthropometric, dietary, and hormonal correlates of serum adiponectin in Asian American women. Nutr Cancer 63: 549-557.
37. Tian C, Ye X, Zhang R, Long J, Ren W, et al. (2013) Green Tea Polyphenols Reduced Fat Deposits in High Fat-Fed Rats via erk1/2-PPARgamma-Adiponectin Pathway. PLoS One 8: e53796.
38. Olofsson SO, Wiklund O, Boren J (2007) Apolipoproteins A-I and B: biosynthesis, role in the development of atherosclerosis and targets for intervention against cardiovascular disease. Vasc Health Risk Manag 3: 491-502. (Pubitemid 47542610)
39. Goto T, Saito Y, Morikawa K, Kanamaru Y, Nagaoka S (2012) Epigallocatechin gallate changes mRNA expression level of genes involved in cholesterol metabolism in hepatocytes. Br J Nutr 107: 769-773.
40. Li L, Stillemark-Billton P, Beck C, Bostrom P, Andersson L, et al. (2006) Epigallocatechin gallate increases the formation of cytosolic lipid droplets and decreases the secretion of apoB-100 VLDL. J Lipid Res 47: 67-77. (Pubitemid 43107450)
41. Mazzanti G, Menniti-Ippolito F, Moro PA, Cassetti F, Raschetti R, et al. (2009) Hepatotoxicity from green tea: a review of the literature and two unpublished cases. Eur J Clin Pharmacol 65: 331-341.